Journal:
:iranian red crescent medical journal
0
hanifeh mirtavoos mahyari chronic respiratory disease research center, national research institute of tuberculosis and lung disease (nritld), shahid beheshti university of medical sciences, tehran, ir iran
adnan khosravi hematology and medical oncology, chronic respiratory disease research center, national research institute of tuberculosis and lung disease (nritld), shahid beheshti university of medical sciences, tehran, ir iran; hematology and medical oncology, chronic respiratory disease research center, national research institute of tuberculosis and lung disease (nritld), shahid beheshti university of medical sciences, tehran, ir iran. tel: +98-2126109946
zeinab mirtavoos mahyari tehran medical branch, islamic azad university, tehran, ir iran
zahra esfahani monfared mycobacteriology research center, national research institute of tuberculosis and lung disease (nritld), shahid beheshti university of medical sciences, tehran, ir iran
negin khosravi north tehran branch, azad university of tehran, tehran, ir iran
conclusions this study on a limited number of patients treated with adjutant anthracyclins-based regimens, revealed that her2/neu is not a unique strong predictor for outcome, thus according to combination of her2/neu status and other clinical factors, it is necessary to distinguish patients at high risk of recurrence. results her2/neu amplification was identified in 19 (38%) of 50 patients. no...
